MEP47308A - Hfa-suspension formulation of an anhydrate - Google Patents

Hfa-suspension formulation of an anhydrate

Info

Publication number
MEP47308A
MEP47308A MEP-473/08A MEP47308A MEP47308A ME P47308 A MEP47308 A ME P47308A ME P47308 A MEP47308 A ME P47308A ME P47308 A MEP47308 A ME P47308A
Authority
ME
Montenegro
Prior art keywords
anhydrate
hfa
suspension formulation
formulation
suspension
Prior art date
Application number
MEP-473/08A
Other languages
Croatian (hr)
Inventor
Christel Schmelzer
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MEP47308A publication Critical patent/MEP47308A/en
Publication of ME00246B publication Critical patent/ME00246B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Pronalazak se odnosi na formulaciju, sa potisnim gasom, suspenzije, kristalnog anhidrata (1α,2β,4β,5α,7β)-7-[(hidroksidi-2-tienilacetil)oksi]-9,9-dimetil-3-oksa-9-azo-niatriciklo[3.3.1.02.4] nonan-bromida.The invention relates to the formulation, with propellant, of a suspension, of crystalline anhydrate (1α, 2β, 4β, 5α, 7β) -7 - [(hydroxides-2-thienylacetyl) oxy] -9,9-dimethyl-3-oxa-9 -azo-niatricyclo [3.3.1.02.4] nonan bromide.

MEP-2008-473A 2002-03-28 2003-03-20 Hfa-suspension formulation of an anhydrate ME00246B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10214264A DE10214264A1 (en) 2002-03-28 2002-03-28 HFA suspension formulations of an anhydrate
PCT/EP2003/002899 WO2003082244A2 (en) 2002-03-28 2003-03-20 Hfa-suspension formulation of an anhydrate

Publications (2)

Publication Number Publication Date
MEP47308A true MEP47308A (en) 2011-02-10
ME00246B ME00246B (en) 2011-05-10

Family

ID=28050990

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-473A ME00246B (en) 2002-03-28 2003-03-20 Hfa-suspension formulation of an anhydrate

Country Status (21)

Country Link
EP (1) EP1492498A2 (en)
JP (1) JP5147158B2 (en)
KR (1) KR101005717B1 (en)
CN (1) CN1642525A (en)
AU (1) AU2003221509B2 (en)
BR (1) BR0308709A (en)
CA (1) CA2479638C (en)
DE (1) DE10214264A1 (en)
EA (1) EA008610B1 (en)
EC (1) ECSP045322A (en)
HR (1) HRP20040890A2 (en)
IL (1) IL163696A0 (en)
ME (1) ME00246B (en)
MX (1) MXPA04009338A (en)
NO (1) NO20044004L (en)
NZ (1) NZ536030A (en)
PL (1) PL371295A1 (en)
RS (1) RS52481B (en)
UA (1) UA79776C2 (en)
WO (1) WO2003082244A2 (en)
ZA (1) ZA200405637B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101166738B (en) * 2005-05-02 2011-06-01 贝林格尔·英格海姆国际有限公司 Novel crystalline forms of tiotropium bromide
MX2007013691A (en) * 2005-05-02 2008-01-21 Boehringer Ingelheim Int Crystalline forms of tiotropium bromide.
AU2015201037C1 (en) * 2009-05-29 2017-07-27 Pearl Therapeutics, Inc. Respiratory delivery of active agents
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
TWI695723B (en) * 2009-05-29 2020-06-11 美商沛爾醫療股份有限公司 Compositions for respiratory delivery of active agents and associated methods and systems
US20140275517A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
CN114712337A (en) * 2016-09-19 2022-07-08 墨西哥氟石股份公司 Pharmaceutical composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (en) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Esters of thienyl carboxylic acids with amino alcohols, their quaternization products, processes for their preparation and medicaments containing them
PT1102579E (en) * 1998-08-04 2003-07-31 Jago Res Ag MEDICINAL AEROSOL FORMULATIONS
GB0009606D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0009592D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009605D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
EP1341538B1 (en) * 2000-10-31 2009-12-23 Boehringer Ingelheim Pharma GmbH & Co.KG Medicament compositions with salts of tiotropium and epinastin for the therapy of respiratory diseases
DE10113366A1 (en) * 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Medicament for treating inflammatory or obstructive respiratory diseases, e.g. asthma or chronic obstructive pulmonary disease, containing synergistic combination of anticholinergic agent and endothelin antagonist
DE10111058A1 (en) * 2001-03-08 2002-09-12 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics and NK¶1¶ receptor antagonists

Also Published As

Publication number Publication date
WO2003082244A2 (en) 2003-10-09
KR101005717B1 (en) 2011-01-05
WO2003082244A3 (en) 2004-02-05
NO20044004L (en) 2004-10-05
CN1642525A (en) 2005-07-20
JP5147158B2 (en) 2013-02-20
KR20040098022A (en) 2004-11-18
EP1492498A2 (en) 2005-01-05
DE10214264A1 (en) 2003-10-16
JP2005527550A (en) 2005-09-15
BR0308709A (en) 2005-01-04
AU2003221509A1 (en) 2003-10-13
EA200401159A1 (en) 2005-04-28
CA2479638C (en) 2011-01-04
PL371295A1 (en) 2005-06-13
ZA200405637B (en) 2005-07-27
RS52481B (en) 2013-02-28
CA2479638A1 (en) 2003-10-09
IL163696A0 (en) 2005-12-18
UA79776C2 (en) 2007-07-25
EA008610B1 (en) 2007-06-29
MXPA04009338A (en) 2005-01-25
ME00246B (en) 2011-05-10
HRP20040890A2 (en) 2005-06-30
AU2003221509B2 (en) 2008-01-24
YU86004A (en) 2006-08-17
ECSP045322A (en) 2005-01-28
NZ536030A (en) 2006-07-28

Similar Documents

Publication Publication Date Title
EA200401142A1 (en) MICRONIZED CRYSTALLINE TIOTROPYBROMID
EA200300666A1 (en) METHOD OF OBTAINING OWNER OF ANTICHOLINERGIC ACTION OF THIOTROPYBROMID
MEP40008A (en) Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament
MEP62008A (en) Crystalline anticholinergic, method for its production, and use thereof in the production of a drug
CY1105543T1 (en) ANTICHOLINERGIC CONTAINING HFA SUSPENSION PREPARATIONS
DK1401837T3 (en) Purine derivatives as A2B adenosine receptor antagonists
DK1087960T3 (en) Macrocyclic analogues and methods for their use and preparation
RS51436B (en) Triazol tropane derivatives as ccr5 moudlators
ES2162614T1 (en) FILM FORMATION COMPOSITIONS THAT INCLUDE MODIFIED ALMIDONES AND IOTA-CARRAGAENINE AND METHOD TO PRODUCE SOFT CAPSULES USING THE SAME.
ES2143238T3 (en) DERIVATIVES OF 1- (PIPERIDINIL SUBSTITUTED IN POSITIONS 1,2) -PIPERAZINES SUBSTITUTED IN POSITION 4.
AR023231A1 (en) STABILIZED BULK SOLUTIONS, MANUFACTURING METHOD AND USE OF THE SAME FOR BIOENSUCIATION CONTROL
MEP47308A (en) Hfa-suspension formulation of an anhydrate
GB2380675A (en) Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives
ES2158345T3 (en) DERIVATIVES OF PIPERAZINO AS ANTAGONISTS OF NEUROQUININA.
NZ228889A (en) Fused tri- or tetracyclic heterocyclic compounds and pharmaceutical compositions
AR009413A1 (en) A COMPOUND, WHICH IS A DERIVATIVE OF BENZOHETEROCICLICO DISTAMICINA, ITS USE, A PROCEDURE TO PRODUCE IT AND A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
EP0716083A4 (en) Benzazepine derivative, pharmaceutical composition containing the same, and intermediate for the same
WO1994019343A3 (en) Novel use as anti-inflammatory agents for bis-heterocyclic compounds and pharmaceutical compositions thereof
PE20020758A1 (en) MANUFACTURING METHOD OF COMBINED VACCINE
ECSP034921A (en) CRYSTALLINE ANTI-POLYNERGIC, METHOD FOR PRODUCTION, AND USE OF THE SAME IN THE PRODUCTION OF A DRUG
IT1263304B (en) FOG TUNNEL